公司問答 | 君實生物:特瑞普利單抗鼻咽癌適應症已經順利完成了生產基地的許可前檢查
格隆匯6月1日丨有投資者在互動平台向君實生物提問:請問到目前5月29日為止,公司是否已經收到FDA生產現場進行核查的正式通知?君實生物迴應:關於公司特瑞普利單抗鼻咽癌適應症於美國FDA的上市申請,截至目前已經順利完成了生產基地的許可前檢查(Pre-License Inspection,PLI)。公司合作伙伴Coherus正在準備特瑞普利單抗在美國商業化的相關工作。相關上市申請的後續進展歡迎持續關注公司公吿及官方新聞。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.